Roche to make $1.9bn acquisition
Sanofi to acquire Ablynx for €3.9bn
Sanofi reveals new R&D strategy
blackjack3d / iStockphoto.com
Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Bioverativ, mergers & acquisitions, haemophilia, therapies, M&A, strategy, blood disorders